• Adial named Matthew Davidson as chief development officer, expanding its executive leadership team alongside the Azora Therapeutics business combination.
• Julie Saiki joined as executive vice president of strategy as the company builds out leadership tied to the Azora transaction.
• The appointments were disclosed with the June 12, 2026 close of the first USD 32 million tranche of an up to USD 64 million private placement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606160800PRIMZONEFULLFEED9747436) on June 16, 2026, and is solely responsible for the information contained therein.